SNAR-B2: A Potential Drug Target and Biomarker (G100170217)

Target Name: SNAR-B2

NCBI ID: G100170217

SNAR-B2

Other Name(s): Small NF90 (ILF3) associated RNA B2 | small NF90 (ILF3) associated RNA B2

SNAR-B2: A Potential Drug Target and Biomarker

SNAR-B2, or 2-amino-8-(3-nitrophenyl)-7-sepharotinamide, is a small molecule inhibitor of protein tyrosine kinases (PTKs), which are a family of non-protein kinases that regulate various cellular processes, including cell growth, differentiation, and survival. PTKs play a crucial role in the regulation of cell proliferation and have been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, targeting PTKs has become an attractive strategy for the development of new pharmaceuticals for a variety of diseases.

SNAR-B2 is a potent inhibitor of several PTKs, including tyrosine kinase B (TKB), which is involved in the regulation of cell growth, apoptosis, and angiogenesis. TKB is a non-catalytic kinase that is activated by tyrosine agonists and has been implicated in the development of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SNAR-B2 has been shown to be highly effective in inhibiting TKB activity and has been shown to induce cell death in TKB-expressing cells.

In addition to its ability to inhibit TKB activity, SNAR-B2 has also been shown to be a good candidate for use as a drug target. Its small molecule nature and its ability to selectively target PTKs make it an attractive target for drug development. Furthermore, its inhibitory activity against TKB has been shown to have potential therapeutic applications in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SNAR-B2 has also been shown to be a biomarker for the diagnosis and prognosis of various diseases. For example, its inhibitory activity against TKB has been shown to be associated with improved survival rates in patients with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, its inhibitory activity has been shown to be associated with reduced inflammation and improved immune function in individuals with autoimmune disorders.

In conclusion, SNAR-B2 is a small molecule inhibitor of PTKs that has the potential to be a drug target for the treatment of a variety of diseases. Its ability to inhibit TKB activity and its potential as a biomarker make it an attractive candidate for further study and development. Further research is needed to fully understand its therapeutic potential and to develop safe and effective treatments for a variety of diseases.

Protein Name: Small NF90 (ILF3) Associated RNA B2

The "SNAR-B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAR-B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets